Search Results - "Cuentas, E. Parra"

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study by de Sousa, L. Guimaraes, Liu, S., Bhosale, P., Altan, M., Darbonne, W., Schulze, K., Dervin, S., Yun, C., Mahvash, A., Verma, A., Futreal, A., Gite, S., Cuentas, E. Parra, Cho, W.C., Wistuba, I., Yao, J.C., Woodman, S.E., Halperin, D.M., Ferrarotto, R.

“…•In this phase II trial of atezolizumab and bevacizumab in advanced MCC patients, the ORR was 64 %, with 27 % complete responses.•Atezolizumab and bevacizumab…”
Get full text

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort by Machado-Rugolo, Juliana, Gutierrez Prieto, Tabatha, Fabro, Alexandre Todorovic, Parra Cuentas, Edwin Roger, Sá, Vanessa Karen, Baldavira, Camila Machado, Rainho, Claudia Aparecida, Castelli, Erick C, Farhat, Cecilia, Takagaki, Teresa Yae, Nagai, Maria Aparecida, Capelozzi, Vera Luiza

“…Although non-small cell lung cancer (NSCLC) remains a deadly disease, new predictive biomarkers have emerged to assist in managing the disease, of which one of…”
Get full text